Showing 5311-5320 of 5644 results for "".
- Heidelberg Engineering Introduces the GMPE Hood Glaucoma Report for Spectralis OCThttps://modernod.com/news/heidelberg-engineering-introduces-the-gmpe-hood-glaucoma-report-for-spectralis-oct/2479582/Heidelberg Engineering announced that the Hood Glaucoma Report is now available with a software update within the Spectralis OCT Glaucoma Module Premium Edition (GMPE). The GMPE Hood Glaucoma Report highlights
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys With Transitions Light Intelligent Technology in the U.S.https://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-u-s/2479584/Johnson & Johnson Vision announced the US availability of Acuvue Oasys with Transitions Light Intelligent Technology. The contact lenses adapt to changing light, helping eyes recover from bright light up to 5 seconds faster, reducing halos and starbursts at night, and delivering more sight w
- Quantel Medical Receives FDA Approval for ABSolu Ultrasound Platformhttps://modernod.com/news/quantel-medical-receives-fda-approval-for-absolu-ultrasound-platform/2476415/Quantel Medical announced that it has received approval from the FDA for the new A/B/S ultrasound platform: ABSolu. The ABSolu includes a new 5 ring annular technology 20MHz B probe that increases the depth of
- Allergan Agrees to Split CEO, Chairman Roles at Next Leadership Transitionhttps://modernod.com/news/allergan-agrees-to-split-ceo-chairman-roles-at-next-leadership-transition/2476413/Allergan disclosed in a US Securities and Exchange Commission filing on Friday that it has agreed to split its chairman and chief executive roles, both currently held by CEO Brent Saunders, at the next leadership transition. The company said that splitting the roles now, as hedge fund Appaloosa h
- Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMDhttps://modernod.com/news/alkahest-presents-positive-phase-2a-study-results-of-akst4290-for-treatment-naive-wet-amd/2476414/Alkahest shared results from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect an
- Topcon Unveils New Maestro Unlimited OCT System at VEE 2019https://modernod.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/Topcon showcased several innovative new offerings at the Vision Expo East (VEE) conference in New York City. Topcon unveiled the new Maestro Unlimited, which pairs the Maestro 3D OCT with the new Topcon Harmony, a web-based data management application that provides unlimited device connect
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr